Suplementação de coenzima Q10 e redução dos efeitos colaterais da terapêutica com estatinas: uma revisão sistemática / Coenzyme Q10 supplementation and reduction of side effects of statin therapy: a systematic review
DOI:
https://doi.org/10.34117/bjdv7n8-600Keywords:
Ubiquinone, Anticholesteremic Agents e Cholesterol.Abstract
A coenzima Q10 (CoQ10), conhecida também como ubiquinona é um componente essencial da cadeia respiratória mitocondrial. Uma das causas da sua deficiência é o uso crônico de estatinas, classe de medicamentos anticolesterolêmicos largamente prescrito. Sua redução pode ocasionar efeitos colaterais indesejáveis, tais como dispneia, alterações hepáticas, sintomas musculares e/ou gastrointestinais, rabdomiólise, neuropatias periféricas, Diabetes Mellitus tipo 2, dentre outros. Esta revisão literária objetivou entender se a suplementação de CoQ10 reduz os efeitos colaterais provocados pelo uso de estatinas, descrevê-los e indicar qual a dose segura e eficaz para o sucesso dessa estratégia nutricional. Trata-se de uma revisão sistemática da literatura, cuja busca se deu na base de dados MEDLINE/PubMed, de estudos publicados no período entre 2004 a 09/2020, com uso dos descritores e combinação Ubiquinone AND Anticholesteremic Agents e Ubiquinone AND Cholesterol. Foram identificados 462 artigos e após leitura do título, resumo e aplicação dos critérios de exclusão foram incluídos 18 trabalhos científicos para análise. Os estudos apresentaram população e metodologias variadas e os métodos de avaliação dos resultados também foram heterogêneos, principalmente devido a variedade de efeitos colaterais estudados. Dos 18 estudos, dez (66,6%) encontraram algum benefício da suplementação. Foi evidenciado que a dose usual de suplementação (entre 100 e 300 mg) foi capaz de trazer benefícios quanto aos seguintes parâmetros: função diastólica, endotelial e mitocondrial, fadiga, miopatias, dispneia, perda de memória, neuropatia periférica, perfil lipídico, atividade antioxidante e anti-inflamatória e hepatotoxicidade evidenciados a partir de 30 dias de suplementação e, ainda, a redução do risco cardiovascular.
References
Banach M et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clinic Proceedings. 2015; 90(1):24-34.
Caso G, Kelly P, McNurlan M A, Lawson W E. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. The American journal of cardiology. 2007; 99(10):1409-1412.
Flowers N, Hartley L, Todkill D, Stranges S, Rees K. Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2014; (12).
Mabuchi H et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. Journal of atherosclerosis and thrombosis. 2005; 12(2):111-119.
Zlatohlavek L, Vrablik M, Grauova B, Motykova E, Ceska R. The effect of coenzyme Q10 in statin myopathy. Neuro Endocrinol Lett. 2012; 33(2):98-101.
Langsjoen P H, Langsjoen J O, Langsjoen A M, Lucas L A. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. Biofactors. 2005; 25(1?4):147-152.
Mabuchi H et al. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis. 2007; 195(2):182-189.
Young J M et al. Effect of coenzyme Q10 supplementation on simvastatin-induced myalgia. The American journal of cardiology. 2007; 100(9):1400-1403.
Fišar Z, Hroudová J, Singh N, Kop?ivová A, Mace?ková D. Effect of Simvastatin, Coenzyme Q10, Resveratrol, Acetylcysteine and Acetylcarnitine on Mitochondrial Respiration. Folia biologica. 2016; 62(2):53.
Hernández V A, Eriksson E K, Edwards K. Ubiquinone-10 alters mechanical properties and increases stability of phospholipid membranes. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2015; 1848(10):2233-2243.
Prajapati S K, Garabadu D, Krishnamurthy S. Coenzyme Q10 prevents mitochondrial dysfunction and facilitates pharmacological activity of atorvastatin in 6-OHDA induced dopaminergic toxicity in rats. Neurotoxicity research. 2017; 31(4):478-492.
Shen Q, Pierce J D. Supplementation of coenzyme Q10 among patients with type 2 diabetes mellitus. In: Healthcare. 2015; (3):296-309.
Langsjoen P H, Langsjoen J O, Langsjoen A M, Rosenfeldt F. Statin-Associated Cardiomyopathy Responds to Statin Withdrawal and Administration of Coenzyme Q10. The Permanente Journal. 2019.
Bookstaver D A, Burkhalter N A; Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. The American journal of cardiology. 2012; 110(4):526-529.
Skarlovnik A, Jani? M, Lunder M, Turk M, Šabovi?et M. Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study. Medical science monitor: international medical journal of experimental and clinical research. 2014; 20:2183.
Taylor B A, Lorson L, White M, Thompson P D. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015; 238(2):329-335.
Derosa G, D’Angelo A, Maffioli P. Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study. Drug Design, Development and Therapy. 2019; 13: 3647–3655.
Hamilton S J, Chew G T, Watts G F. Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diabetes Care. 2009; 32(5):810-812.
Silver M A, Langsjoen P H, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. The American journal of cardiology. 2004; 94(10):1306-1310.
Buettner C, Greenman R L, Long H, Wu J S. Effects of coenzyme Q10 on skeletal muscle oxidative metabolism in statin users assessed using 31P magnetic resonance spectroscopy: a randomized controlled study. Journal of nature and science. 2016; 2(8).
Diemen M P J et al. Validation of a pharmacological model for mitochondrial dysfunction in healthy subjects using simvastatin: A randomized placebo-controlled proof-of-pharmacology study. European journal of pharmacology. 2017; 815:290-297.
Pek S L T, Tavintharan S, Woon K, Lin L, Ong C N, Lim S C, Sum C F. MicroRNAs as biomarkers of hepatotoxicity in a randomized placebo-controlled study of simvastatin and ubiquinol supplementation. Experimental Biology and Medicine. 2016; 241(3):317-330.
Kuhlman A B, Morville T, Dohlmann T L, Hansen M, Kelly B, Helge J W, Dela F. Coenzyme Q10 does not improve peripheral insulin sensitivity in statin-treated men and women; the LIFESTAT study. Applied Physiology, Nutrition, and Metabolism. 2019; 44(5): 485-492.
Deichmann R E, Lavie C J, Dornelles A C. Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins. The Physician and sportsmedicine. 2012; 40(4):88-95.
Lee B, Tseng Y, Yen C, Lin P. Effects of coenzyme Q10 supplementation (300 mg/diaay) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial. Nutrition journal. 2013; 12(1):142.
Needham M; Mastaglia F L. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscular Disorders. 2014; 24(1):4-15.
Fonseca F A H. Pharmacokinetics of statins. Journal of Brazilian Society of Cardiology. 2005; 85:9-14.